河南翔宇医疗设备股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688626 证券简称：翔宇医疗 公告编号：2023-026 会议召开时间：2023 年 5 月 24 日（星期三）上午 9:00-10:00 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网址： http://roadshow.sseinfo.com） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 17 日(星期三)至 5 月 23 日(星期二)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 xymedical@xyyl.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 河南翔宇医疗设备股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年年度报告、2023 年第一季度报告，为便于广大投资者更全面 深入地了解公司 20 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2023-025 河南翔宇医疗设备股份有限公司 关于参加河南辖区上市公司 2023 年投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，河南翔宇医疗设备股份有限公司定于 2023 年 5 月 18 日（周四）16:00-17:20 参加在全景网举办的"真诚沟通 传递 价值"河南辖区上市公司 2023 年投资者网上集体接待日活动，本次活动将采用 网络远程的方式举行，投资者可登录"全景•路演天下"（http://rs.p5w.net） 参与本次互动交流。 出席本次网上集体接待日活动的人员有：董事、副总经理、董事会秘书郭军 玲女士，财务总监金宏峰先生（如有特殊情况，参会人员将可能进行调整），欢 迎广大投资者积极参与。 特此公告。 河南翔宇医疗设备股份有限公司董事会 2023 年 5 月 15 日 ...

Financial Performance - The company's operating revenue for Q1 2023 reached CNY 143,153,527.80, representing a year-on-year increase of 68.25%[4] - Net profit attributable to shareholders was CNY 37,812,580.60, marking a significant increase of 298.99% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was CNY 32,553,857.41, reflecting a substantial growth of 549.98% year-on-year[4] - Basic and diluted earnings per share were both CNY 0.24, which is a 300% increase from the same period last year[4] - The net profit for Q1 2023 reached CNY 38,592,209.22, up from CNY 8,332,824.99 in Q1 2022, marking a growth of approximately 363.5%[21] - The earnings per share for Q1 2023 were CNY 0.24, compared to CNY 0.06 in Q1 2022, reflecting a 300% increase[22] Cash Flow - The net cash flow from operating activities amounted to CNY 36,450,103.71, an increase of 251.84% compared to the previous year[4] - In Q1 2023, the company generated operating cash inflow of CNY 183,353,703.59, a 72.7% increase from CNY 106,200,506.73 in Q1 2022[25] - The net cash flow from operating activities was CNY 36,450,103.71, compared to a negative cash flow of CNY -24,005,795.51 in the same period last year[25] - The company reported a total cash and cash equivalents balance of CNY 832,260,520.32 as of March 31, 2023, up from CNY 749,152,830.61 at the end of 2022[26] - Investment activities generated a net cash inflow of CNY 27,421,758.09, a significant improvement from a net outflow of CNY -52,946,795.92 in Q1 2022[26] - The company's cash inflow from sales of goods and services was CNY 162,957,664.29, up from CNY 94,386,927.88 in Q1 2022, representing a 72.9% increase[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,427,280,318.30, reflecting a 2.50% increase from the end of the previous year[5] - The total current assets decreased slightly to RMB 1,655,063,836.09 from RMB 1,668,379,570.59, indicating a decline of about 0.8%[17] - The company’s total liabilities increased, with short-term borrowings rising to CNY 58,000,000.00 from CNY 3,000,000.00 at the end of 2022[29] - The total liabilities for Q1 2023 were CNY 452,016,292.46, compared to CNY 428,219,732.64 in Q1 2022, which is an increase of approximately 5.5%[19] - The total assets as of Q1 2023 amounted to CNY 2,427,280,318.30, up from CNY 2,368,078,429.22 in the previous year, showing an increase of about 2.5%[19] Research and Development - Research and development expenses totaled CNY 21,608,723.98, accounting for 15.09% of operating revenue, a decrease of 6.54 percentage points year-on-year[5] - Research and development expenses for Q1 2023 were CNY 21,608,723.98, compared to CNY 18,405,732.79 in Q1 2022, indicating an increase of approximately 17.5%[21] - The company achieved 16 new medical device registrations and a total of 257 registrations, alongside 67 new patents, bringing the cumulative total to 1,318 patents[13] - The company reported a total of 83 new intellectual property rights in the current year, contributing to a cumulative total of 1,596 rights[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,994[9] - The total equity attributable to shareholders of the parent company was CNY 1,962,218,182.98, compared to CNY 1,927,592,482.34 in the previous year, showing an increase of approximately 1.8%[19] Inventory and Investments - The company’s inventory decreased to RMB 217,798,316.59 from RMB 222,820,180.68, reflecting a reduction of approximately 2.3%[17] - The company’s long-term equity investments decreased slightly to RMB 16,717,451.07 from RMB 17,086,737.70, a decline of about 2.2%[17] - The company’s fixed assets decreased to RMB 91,637,608.59 from RMB 93,870,801.11, a decline of about 2.4%[17] - The company’s construction in progress increased to RMB 385,358,997.23 from RMB 314,093,717.93, indicating a growth of approximately 22.7%[17] Recognition and Achievements - The company was recognized as a leading enterprise in intellectual property in Henan Province and approved as a model enterprise for industry-university-research cooperation in China[13]

Financial Performance - The company's operating revenue for 2022 was CNY 488.53 million, a decrease of 6.68% compared to CNY 523.50 million in 2021[23]. - The net profit attributable to shareholders for 2022 was CNY 125.47 million, down 37.85% from CNY 201.90 million in 2021[23]. - The basic earnings per share decreased by 41.48% to CNY 0.79 in 2022 from CNY 1.35 in 2021[24]. - The company's total revenue for the year was CNY 483,871,268.14, representing a year-on-year decrease of 6.19%[150]. - The net cash flow from operating activities for 2022 was CNY 186.70 million, an increase of 12.55% from CNY 165.88 million in 2021[23]. - The gross profit margin for the main business was 66.17%, a decrease of 2.01 percentage points compared to the previous year[147]. - The company reported a significant decrease in financing cash flow due to share repurchase activities, with a net outflow of 117.04 million yuan[147]. Shareholder Returns - The proposed cash dividend for 2022 is CNY 2.40 per 10 shares, totaling CNY 37,812,000, which accounts for 30.14% of the net profit attributable to shareholders[5]. - The company repurchased shares worth CNY 73,270,345.21, representing 58.40% of the net profit attributable to shareholders for 2022[6]. - Total cash dividends distributed, including share repurchases, amount to CNY 111,082,345.21, which is 88.54% of the net profit attributable to shareholders for 2022[6]. Research and Development - The company's R&D expenditure as a percentage of operating revenue increased by 5.81 percentage points to 18.92% in 2022, reflecting a commitment to technological innovation[24]. - R&D expenses amounted to 92.41 million yuan, an increase of 34.70% year-on-year, accounting for 18.92% of total revenue, up 5.81 percentage points from the previous year[35]. - The company has a total of 434 R&D personnel, accounting for 25.48% of the total workforce, with ongoing expansion of R&D centers in various cities[36]. - The company has obtained a total of 1,251 patents and participated in drafting or evaluating 29 national industry standards[122]. - The company is committed to continuous innovation and has established a comprehensive R&D system to support its product development and quality assurance[121]. Product Development and Innovation - The company launched a series of new rehabilitation products, including a comprehensive physical therapy system and a biofeedback-assisted electrical stimulation device, enhancing its product portfolio[44]. - The company has developed a VTE prevention information system to dynamically assess and recommend preventive measures for venous thromboembolism in hospitalized patients[53]. - The company has developed focused shock wave technology for precise treatment, enhancing rehabilitation solutions[77]. - The company has launched a pelvic floor functional magnetic stimulation device in 2022, expanding its product line in magnetic therapy[79]. - The company has developed a spinal decompression traction bed that has received registration certification, targeting treatment for cervical and lumbar diseases[112]. Market Position and Strategy - The company aims to enhance its competitive capabilities and solidify its industry position by focusing on quality, scale, and brand development in the rehabilitation medical device sector[71]. - The company is focusing on expanding its rehabilitation medical equipment market, with a target industry scale exceeding 700 billion by 2020[176]. - The company is actively investing in new product development and technology to meet the growing demand in the rehabilitation sector[176]. - The company aims to enhance its domestic market presence while actively expanding into international markets, focusing on differentiated and systematic rehabilitation solutions[186]. - The company is exploring strategic partnerships and market expansion opportunities to strengthen its position in the rehabilitation medical equipment industry[176]. Regulatory and Compliance - The company achieved ISO9001 and ISO13485 certifications, ensuring compliance with international quality management standards for medical devices[67]. - The company implemented a strict quality management system in compliance with ISO13485, ensuring product quality and safety throughout the production process[45]. - The company has been recognized as a "National Technology Innovation Demonstration Enterprise" and received the "Provincial Governor Quality Award" in 2022[70]. Industry Trends and Challenges - The rehabilitation medical device industry faces high technical and regulatory barriers, requiring companies to possess advanced technology and production capabilities[66]. - The competitive landscape in the rehabilitation device market is intensifying, with increased capital influx and market integration, posing a risk to market share if growth expectations are not met[140]. - The industry is moving towards more compact and portable devices to address space limitations in healthcare settings, facilitating easier transfer and precise functionality[88]. - The home healthcare market is expected to grow significantly due to aging populations and increased health awareness, presenting a substantial opportunity for rehabilitation devices[89]. Employee and Talent Development - The average salary of R&D personnel rose to 12.49 million RMB, compared to 10.87 million RMB in the previous year, indicating a focus on attracting and retaining talent[120]. - The company emphasizes talent development, focusing on training middle management and enhancing the skills of frontline employees to align with business growth[48]. - The company has resident after-sales engineers in all 31 provincial-level administrative regions, providing proactive after-sales service to enhance customer engagement[131].

河南翔宇医疗设备股份有限公司 投资者关系活动记录表 证券代码：688626 证券简称：翔宇医疗 编号：2022-003 1 河南翔宇医疗设备股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|----------------------------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | | | 媒体采访 | 业绩说明会 | | | 投资者关系 | 新闻发布会 | 路演活动 | | | 活动类别 | 现场参观 | | | | | 其他 （券商策略会） | | | | | | | | | 参与单位 名称 | 业绩说明会参与投资者 | | | | 时间 | 2022 年 5 月 17 日 | | | | 地 ...

河南翔宇医疗设备股份有限公司 投资者关系活动记录表 证券代码：688626 证券简称：翔宇医疗 编号：2022-004 1 河南翔宇医疗设备股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------|---------------------------------------|----------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | | 媒体采访 | 业绩说明会 | | 投资者关系 | 新闻发布会 | 路演活动 | | 活动类别 | 现场参观 | | | | 其他 （线上策略会） | | | 参与单位 名称 | 人保资产、中信建投证券 | | | | | | | 时间 | 2022 年 6 月 16 日 | | | 地点 | 腾讯会议 | | | | 董事长、总经理、技术总监：何永正 | | | 上市公司接 | 副总经理、董秘：魏作钦 财务总监：李瑾 | | | 待人员姓名 | | | | | 证券事务代表：吴利东 证券专员：陈剑 | | | | 速发 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥135,635,534.31, representing a year-over-year increase of 1.09%[6] - The net profit attributable to shareholders for Q3 2022 was ¥52,906,099.84, showing a significant increase of 17.34% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥30,186,272.16, reflecting a decrease of 20.21% year-over-year[10] - The basic and diluted earnings per share for Q3 2022 were both ¥0.33, a decline of 33.33% compared to the previous year[10] - Total operating revenue for the first three quarters of 2022 reached CNY 356,526,790.54, a slight increase from CNY 350,974,556.35 in the same period of 2021[34] - Net profit for the third quarter of 2022 was CNY 90,251,261.58, down from CNY 130,505,114.47 in the previous year[36] - Earnings per share for the third quarter were CNY 0.58, compared to CNY 0.87 in the same quarter of 2021[39] Assets and Liabilities - The company's total assets at the end of Q3 2022 amounted to ¥2,198,974,328.70, a slight increase of 0.75% from the end of the previous year[10] - The total liabilities increased to CNY 292,159,566.78 from CNY 236,967,892.99 year-on-year[34] - The total equity decreased to CNY 1,906,814,761.92 from CNY 1,945,581,842.01 year-on-year[34] - The total equity attributable to shareholders decreased by 2.07% to ¥1,895,032,614.31 compared to the end of the previous year[10] Cash Flow - The company reported a net cash flow from operating activities of ¥89,377,803.45, which increased by 25.03% year-to-date[10] - In the first three quarters of 2022, the net cash flow from operating activities was ¥89,377,803.45, an increase of 25% compared to ¥71,487,504.46 in the same period of 2021[44] - Cash inflow from operating activities totaled ¥520,332,766.72, up from ¥448,259,097.88 in the previous year, reflecting a growth of approximately 16%[44] - The cash outflow from operating activities increased to ¥430,954,963.27 from ¥376,771,593.42, representing a rise of about 14%[44] - The company reported a net cash flow from financing activities of -¥124,338,824.46, contrasting with a positive cash flow of ¥943,116,905.55 in the previous year[47] - The ending balance of cash and cash equivalents was ¥721,936,846.52, down from ¥768,332,442.15 at the end of the previous year[47] Research and Development - Research and development expenses totaled ¥22,548,559.49 for Q3 2022, an increase of 37.45% year-over-year, accounting for 16.62% of operating revenue[10] - Research and development expenses for the first three quarters of 2022 were CNY 66,082,833.18, up from CNY 45,656,969.46 in the previous year[34] - The company plans to continue optimizing its R&D personnel structure and increasing investment in R&D activities to drive future growth[12] Intellectual Property and Innovation - The company obtained 14 new medical device registration certificates, bringing the total to 236[21] - A total of 77 new patents were granted, increasing the cumulative total to 1,278[21] - The company has a total of 2,206 intellectual property applications, with 1,534 granted[24] - The company was recognized as a "National Technology Innovation Demonstration Enterprise" in 2022[23] - The company led the establishment of an industrial internet cloud platform for rehabilitation medical equipment, which was officially recognized by the Henan provincial expert group[23] - The company received the first prize in the "Technology Innovation Award" from the China Rehabilitation Medical Association for a project on key rehabilitation diagnostic equipment[23] Other Financial Metrics - Cash and cash equivalents decreased from ¥829,615,619.99 in 2021 to ¥724,592,013.03 in 2022[26] - The company’s inventory increased from ¥159,404,577.05 in 2021 to ¥204,166,479.46 in 2022[29] - The company’s long-term equity investments increased from ¥16,714,698.99 in 2021 to ¥18,661,676.59 in 2022[29] - Deferred income increased to CNY 63,783,548.77 from CNY 53,723,412.32 year-on-year[34] - The company reported a financial expense of CNY -19,290,438.51, compared to CNY -15,140,697.15 in the previous year[36] - Investment income for the third quarter was CNY 10,640,535.89, significantly higher than CNY 5,813,168.24 in the same period last year[36] - Employee compensation payments rose to ¥139,586,947.02 from ¥110,932,348.93, reflecting an increase of about 26%[44] - The cash received from tax refunds increased to ¥6,232,785.59 from ¥3,798,020.33, showing a growth of approximately 64%[44]

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, reaching approximately 500 million RMB, representing a growth of 25% compared to the same period last year[1]. - Xiangyu Medical reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2022, representing a 20% growth year-over-year[23]. - The company achieved operating revenue of ¥220,891,256.23 in the first half of 2022, representing a year-on-year increase of 1.88%[30]. - The company achieved a total revenue of 28,455.95 million RMB, with a net profit of 4,353.43 million RMB, representing a significant increase compared to the previous period[100]. - Net profit attributable to shareholders decreased by 53.67% to ¥40,004,174.26 compared to the same period last year[30]. - The net cash flow from operating activities fell by 49.61% to ¥18,278,303.10, primarily due to increased material procurement and employee compensation expenses[33]. - Basic earnings per share dropped by 57.63% to ¥0.25, while diluted earnings per share also stood at ¥0.25[30]. - The weighted average return on net assets decreased by 4.51 percentage points to 2.07%[30]. Market Expansion and Strategy - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 20% year-over-year, aiming to reach 600 million RMB[1]. - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish partnerships with local distributors by the end of 2022[1]. - Future outlook indicates a projected revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[23]. - Xiangyu Medical plans to enter new markets in Southeast Asia, targeting a market share of 10% within the next two years[23]. - The company is actively expanding its product line and market presence, particularly in grassroots medical markets, to drive future growth[146]. Research and Development - Research and development expenditure has increased by 30%, totaling 80 million RMB, to support innovation and product enhancement[1]. - The company is investing heavily in R&D, allocating 10% of its revenue to develop innovative rehabilitation devices and technologies[23]. - R&D expenses accounted for 19.71% of operating revenue, an increase of 6.22 percentage points compared to the previous year[30]. - The company has developed over 500 proprietary products across 20 categories, providing a comprehensive range of rehabilitation medical devices[46]. - The company obtained 42 new medical device registration certificates, bringing the total to 222, and added 175 new patents, totaling 1,201 patents[66]. - The company has developed key technologies in over 30 fields, including shock wave therapy and magnetic therapy, which are protected by its intellectual property rights[102]. - The company has a comprehensive ability to convert clinical needs into products, ensuring a wide range of rehabilitation medical device offerings[118]. Product Development and Innovation - New product development is underway, with three innovative medical devices expected to launch by Q4 2022, which are anticipated to contribute an additional 50 million RMB in revenue[1]. - New product lines, including advanced rehabilitation equipment, are set to launch in Q3 2022, anticipated to contribute an additional 50 million RMB in revenue[23]. - The company has launched new products, including a balance function training and assessment system, which utilizes advanced sensor technology[108]. - The company is focusing on developing a multi-module integrated rehabilitation device, with a total investment of ¥429.90 million and a current period investment of ¥27.75 million[78]. - The company is enhancing its rehabilitation training equipment with intelligent features to assist patients with early standing and walking training[76]. Financial Management and Cost Control - The company has implemented cost-reduction strategies, aiming to decrease operational expenses by 5% in the next fiscal year[1]. - The company has a net asset return risk due to the growth of net assets outpacing operating performance growth[137]. - The company faces risks from potential price reductions in the rehabilitation medical device sector due to national procurement policies[138]. - The company is exposed to intensified market competition as the rehabilitation device market attracts more capital and increases in marketization[139]. Corporate Governance and Compliance - The company has established a profit distribution plan in accordance with its articles of association post-IPO[194]. - The company confirmed that its IPO prospectus and related disclosures do not contain false records or misleading statements, and it will bear legal responsibility for their accuracy[194]. - The company will compensate investors for losses incurred due to any false disclosures recognized by regulatory authorities[197]. - The company’s management has committed to not transferring benefits unfairly to other parties and to adhere to the established compensation system linked to performance measures[191]. Environmental and Social Responsibility - The company has implemented pollution control measures, including high-efficiency dust removal and VOC treatment facilities, ensuring compliance with environmental regulations[167]. - The company promotes sustainability through initiatives like solar power generation and waste reduction practices[173]. - The company actively responds to the national "dual carbon" policy, implementing energy-saving and emission-reduction strategies, optimizing processes to improve material and equipment utilization, and reducing energy consumption to lower carbon emissions[174].

Financial Performance - The company's operating revenue for 2021 was approximately ¥523.50 million, representing a 5.65% increase compared to ¥495.51 million in 2020[32]. - The net profit attributable to shareholders for 2021 was approximately ¥201.90 million, a 2.87% increase from ¥196.26 million in 2020[32]. - The company's total assets increased by 122.36% to approximately ¥2.18 billion at the end of 2021, compared to ¥981.53 million at the end of 2020[32]. - The net assets attributable to shareholders grew by 160.26% to approximately ¥1.94 billion at the end of 2021, up from ¥743.52 million at the end of 2020[32]. - The basic earnings per share for 2021 was ¥1.35, a decrease of 17.68% from ¥1.64 in 2020[32]. - The net cash flow from operating activities for 2021 was approximately ¥165.88 million, a decrease of 23.35% from ¥216.40 million in 2020[32]. - The gross margin for the latest quarter was reported at 45%, an increase from 40% in the previous year, indicating improved operational efficiency[23]. - The gross profit margin for the main business was 68.18%, an increase of 0.47 percentage points compared to the previous year[193]. Dividend and Share Capital - The company plans to distribute a cash dividend of RMB 3.80 per 10 shares, totaling RMB 60.8 million, which accounts for 30.11% of the net profit attributable to shareholders for 2021[6]. - The total share capital as of December 31, 2021, is 160 million shares[6]. - The company has not proposed any capital reserve transfer to increase share capital or bonus shares for the year[6]. Research and Development - The company is investing heavily in R&D, with a budget allocation of 200 million RMB for the development of innovative rehabilitation technologies[23]. - Research and development expenses accounted for 13.11% of operating revenue in 2021, an increase of 2.71 percentage points from 10.40% in 2020[32]. - The total R&D expenditure for the current year is ¥68,605,758.74, an increase of 33.08% from ¥51,551,364.79 in the previous year[122]. - The company has submitted 317 patent applications during the reporting period, including 29 invention patents, and received 274 authorized patents, enhancing its product series significantly[46]. - The company has developed over 30 core technologies, including dynamic sensing feedback technology, which supports its product innovation in rehabilitation[163]. - The company has established a comprehensive R&D system, integrating production, academia, and research, which enhances its innovation capabilities[162]. Market Expansion and Strategy - Future outlook indicates a projected revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies[23]. - Xiangyu Medical plans to enter new markets, targeting Southeast Asia, with an expected market entry by Q3 2022[23]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[35]. - The company aims to leverage its capital market advantages to strengthen its core competitiveness and expand its main business[57]. - The company is focusing on expanding its product portfolio in rehabilitation and traditional medicine, enhancing its competitive position in the market[149]. Operational Efficiency and Quality Management - The company has established a comprehensive quality management system in compliance with medical device regulations, ensuring strict quality control throughout the product lifecycle[51]. - The company is advancing its digital transformation through the implementation of an ERP system, CRM system, and the development of a unique device identification (UDI) system for better quality management[50]. - The company has engaged in strategic initiatives to enhance operational efficiency and explore potential mergers and acquisitions[35]. - The company has implemented a procurement model based on comprehensive evaluation principles, establishing long-term partnerships with potential suppliers[66]. Product Development and Innovation - The company has developed a complete product system that includes devices for pain management, orthopedic rehabilitation, and neurological recovery[58]. - The company is working on an "exercise-assisted rehabilitation training system," which embodies the concept of rehabilitation robots, aimed at improving rehabilitation efficiency and quality[94]. - The company has achieved market entry certification for multiple new products, enhancing its competitive position in the rehabilitation equipment market[143]. - The company has developed new core technologies, including a balance function reconstruction technology that allows for rapid assessment of balance capabilities[108]. Recognition and Awards - Xiangyu Medical was recognized as a "National Enterprise Technology Center" and received multiple awards from provincial authorities, enhancing its reputation in the industry[54]. - The company has been recognized as a "Demonstration Enterprise of Intellectual Property" and an "Innovation Leading Enterprise" by provincial authorities, reflecting its focus on innovation[54]. - The company has been recognized as a national-level specialized and innovative "little giant" enterprise since 2019[120]. Risks and Challenges - The company faces risks related to technology innovation and competition in the rapidly growing rehabilitation medical device market[177]. - The company is exposed to financial risks, including potential declines in return on equity due to slower revenue growth compared to net asset growth[181]. - The company is facing risks from intensified market competition and potential impacts from public health events, which could affect future performance[186].

Financial Performance - The company's operating revenue for Q1 2022 was ¥85,084,216, representing a decrease of 15.57% compared to the same period last year [6] - Net profit attributable to shareholders was ¥9,477,068.41, down 72.25% year-over-year [6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,008,421.84, a decline of 82.69% compared to the previous year [6] - Basic and diluted earnings per share were both ¥0.06, down 71.43% year-over-year [6] - Net profit for Q1 2022 was ¥8,332,824.99, a decline of 75.5% from ¥33,973,422.33 in Q1 2021 [32] - Earnings per share for Q1 2022 was ¥0.06, down from ¥0.21 in Q1 2021 [32] - Operating profit for Q1 2022 was ¥12,978,501.28, down 50.5% from ¥26,215,491.98 in Q1 2021 [49] - Net profit for Q1 2022 was ¥11,031,290.26, a decline of 50.0% compared to ¥22,072,885.83 in Q1 2021 [52] - The total comprehensive income for Q1 2022 was ¥8,332,824.99, significantly lower than ¥33,973,422.33 in Q1 2021 [32] - The total comprehensive income for Q1 2022 was ¥11,031,290.26, which is the same as the net profit, reflecting no other comprehensive income items [52] Cash Flow - The net cash flow from operating activities was -¥24,005,795.51, a significant decrease of 564.24% year-over-year [6] - Cash flow from operating activities in Q1 2022 was negative at -¥22,746,809.97, compared to a positive cash flow of ¥11,484,771.87 in Q1 2021 [54] - The company reported a decrease in cash received from operating activities, totaling 106,200,506.73 RMB compared to 126,169,228.08 RMB previously [38] - The company reported a total cash inflow from operating activities of ¥104,153,856.12 in Q1 2022, down from ¥114,147,244.76 in Q1 2021 [54] - Total cash inflow from investment activities was 596,530,207.27 RMB, while cash outflow was 649,477,003.19 RMB, resulting in a net cash flow of -52,946,795.92 RMB [38] - Cash and cash equivalents at the end of the period amounted to 749,152,830.61 RMB, down from 1,506,843,837.25 RMB in the previous period [40] Research and Development - Research and development expenses totaled ¥18,405,732.79, an increase of 43.48% compared to the same period last year [8] - R&D expenses accounted for 21.63% of operating revenue, up 8.90 percentage points year-over-year [8] - Research and development expenses rose to ¥18,405,732.79 in Q1 2022, compared to ¥12,827,992.23 in Q1 2021, reflecting a 43.7% increase [31] - Research and development expenses for Q1 2022 were ¥10,725,680.83, slightly up from ¥10,615,512.21 in Q1 2021 [46] - The company plans to continue strengthening R&D and sales investments, which has led to a temporary decline in net profit [11] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,154,381,313.03, a decrease of 1.29% from the end of the previous year [8] - As of March 31, 2022, the company's total current assets were approximately RMB 1.67 billion, a decrease from RMB 1.72 billion at the end of 2021 [23] - The company's cash and cash equivalents decreased to approximately RMB 751.49 million from RMB 829.62 million at the end of 2021, representing a decline of about 9.4% [23] - The company's total liabilities decreased from RMB 181.42 million to RMB 145.75 million, a reduction of approximately 19.7% [27] - The company's total assets as of March 31, 2022, were approximately RMB 2.15 billion, down from RMB 2.18 billion at the end of 2021 [27] - The company's accounts payable decreased significantly from RMB 33.15 million to RMB 21.47 million, a decline of about 35.3% [27] - Total liabilities amounted to ¥200,466,646.03, down from ¥236,967,892.99 in the previous year [31] - Total liabilities rose to 256,527,854.75 RMB compared to 232,375,085.17 RMB in the previous period [44] Intellectual Property - In Q1 2022, the company obtained 9 new medical device registration certificates, bringing the total to 189 [18] - The company added 104 new patents in Q1 2022, with a cumulative total of 1,155 patents [18] - The company reported a total of 88 new applications for various intellectual properties in Q1 2022, with 141 granted, bringing cumulative totals to 1,977 applications and 1,370 granted [19]